BIA
RCUS icon

Bell Investment Advisors’s Arcus Biosciences RCUS Stock Holding History

Bell Investment Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37
Closed -$765 – 1968
2022
Q4 		$765 Buy
37
+16
+76% +$440 ﹤0.01% 1657
2022
Q3 		$1K Hold
21
– – ﹤0.01% 1543
2022
Q2 		$1K Buy
+21
New +$514 ﹤0.01% 1564
2021
Q4 		– Sell
-18
Closed -$1K – 1916
2021
Q3 		$1K Buy
+18
New +$560 ﹤0.01% 1534

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bell Investment Advisors's RCUS Position: Q1 2023 in Review

Bell Investment Advisors sold out of Arcus Biosciences (RCUS) in Q1 2023, closing a stake of 37 shares — an estimated $765 sold.

Bell Investment Advisors first reported a position in RCUS in Q3 2021 and held it in 4 quarters. The position peaked at $1K in Q3 2022. 179 funds tracked by Wall St. Rank hold RCUS as of Q1 2023.

  • Bell Investment Advisors reported no remaining Arcus Biosciences position as of Q1 2023 after selling out during the quarter.
  • Bell Investment Advisors sold 37 Arcus Biosciences shares in Q1 2023, an estimated $765.
  • Bell Investment Advisors first reported a position in Arcus Biosciences in Q3 2021 and held it in 4 quarters.
  • Bell Investment Advisors's Arcus Biosciences position peaked at $1K in Q3 2022.
  • 179 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2023.

Based on Bell Investment Advisors's 13F filing for Q1 2023, filed 10 May 2023.